Payment overview · 2025
General Payments
$222.68
11 reported records · 4 companies
Healthcare provider profile · identity verified
Victor Scott Taylor, MD
Allopathic & Osteopathic Physicians|Family Medicine · GULF SHORES, AL · NPI 1790724458
Verified facts
What the public records show
CMS Open Payments records show Victor Scott Taylor, MD received $222.68 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.32 | 41.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.56 | 34.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.19 | 16.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.61 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $222.68 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.56 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.22 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 232 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
232 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 802 | 208 |
| Atorvastatin Calcium | Atorvastatin Calcium | 765 | 220 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 693 | 214 |
| Lisinopril | Lisinopril | 676 | 187 |
| Amlodipine Besylate | Amlodipine Besylate | 641 | 187 |
| Omeprazole | Omeprazole | 553 | 163 |
| Losartan Potassium | Losartan Potassium | 509 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 114 |
| Metformin Hcl | Metformin Hcl | 341 | 111 |
| Gabapentin | Gabapentin | 334 | 84 |
| Trazodone Hcl | Trazodone Hcl | 333 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 326 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 317 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 284 | 81 |
| Alprazolam | Alprazolam | 279 | 62 |
| Simvastatin | Simvastatin | 271 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 260 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 74 |
| Ozempic | Semaglutide | 232 | 53 |
| Sertraline Hcl | Sertraline Hcl | 228 | 65 |
| Meloxicam | Meloxicam | 211 | 71 |
| Furosemide | Furosemide | 202 | 59 |
| Allopurinol | Allopurinol | 186 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 53 |
| Eliquis | Apixaban | 178 | 48 |
| Montelukast Sodium | Montelukast Sodium | 176 | 48 |
| Lovastatin | Lovastatin | 166 | 45 |
| Mounjaro | Tirzepatide | 159 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 131 | 36 |
| Potassium Chloride | Potassium Chloride | 131 | 44 |
| Carvedilol | Carvedilol | 129 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 39 |
| Atenolol | Atenolol | 121 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 23 |
| Donepezil Hcl | Donepezil Hcl | 111 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 27 |
| Synthroid | Levothyroxine Sodium | 100 | 22 |
| Tramadol Hcl | Tramadol Hcl | 94 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 25 |
| Famotidine | Famotidine | 90 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 34 |
| Clonazepam | Clonazepam | 87 | 16 |
| Azithromycin | Azithromycin | 80 | 68 |
| Ezetimibe | Ezetimibe | 79 | 27 |
| Spironolactone | Spironolactone | 76 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 25 |
| Metformin Hcl Er | Metformin Hcl | 74 | 26 |
| Buspirone Hcl | Buspirone Hcl | 72 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 69 | 21 |
| Estradiol | Estradiol | 66 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 27 |
| Lorazepam | Lorazepam | 62 | 12 |
| Trulicity | Dulaglutide | 62 | 16 |
| Irbesartan | Irbesartan | 61 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 16 |
| Bupropion Xl | Bupropion Hcl | 58 | 21 |
| Celecoxib | Celecoxib | 58 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 16 |
| Finasteride | Finasteride | 56 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 16 |
| Fenofibrate | Fenofibrate | 55 | 17 |
| Prednisone | Prednisone | 55 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 17 |
| Mirtazapine | Mirtazapine | 52 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 38 |
| Temazepam | Temazepam | 52 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 18 |
| Propranolol Hcl | Propranolol Hcl | 51 | 17 |
| Pregabalin | Pregabalin | 49 | 14 |
| Testosterone | Testosterone | 49 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 41 |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | 19 |
| Jardiance | Empagliflozin | 44 | 12 |
| Acyclovir | Acyclovir | 42 | 16 |
| Valacyclovir | Valacyclovir Hcl | 41 | 20 |
| Alendronate Sodium | Alendronate Sodium | 39 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 39 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 36 | 13 |
| Farxiga | Dapagliflozin Propanediol | 35 | 12 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 28 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 26 |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Valsartan | Valsartan | 29 | 11 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 15 |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 22 |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 22 |
| Diazepam | Diazepam | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Dutasteride | Dutasteride | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $222.68 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error